Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Lung Cancer Clinical Trial

Official title:

Safety and Efficacy of Aprepitant for Chemotherapy-Induced Nausea and Vomiting in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02445872
• Other study ID #: ZYTOP1502
• Status: Not yet recruiting
• Phase: Phase 2
• First received: April 5, 2015
• Last updated: December 8, 2015
• Start date: December 2015
• Est. completion date: May 2016

Study information

• Verified date: August 2015
• Source: Zhejiang University
• Contact: Qiong Zhao, MD
• Phone: 0571-87236802
• Email: doczq.2008[@]gmail.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Aprepitant is an oral neurokinin-1(NK-1) antagonist which is used for the prevention of chemotherapy-induced nausea and vomiting (CINV). This phase II clinical trial was designed to evaluate the efficacy of aprepitant in the prevention of CINV with lung cancer patients receiving 3-day cisplatin-based chemotherapy.

Description:

Patients pathologic diagnosed of advanced non-small cell lung cancer, according to NCCN non-small cell lung cancer guide line(2015 V1).The patient should receive a 3-day cisplatin-based chemotherapy, are randomized divided into two groups, aprepitant group and placebo group. In aprepitant group, patients would receive aprepitant(125 mg po at day1, 80 mg at day2-3) combination with palonosetron and dexamethasone(5mg iv at day1-3, 3.75mg po at day4-5). In placebo group patients would receive palonosetron and dexamethasone(5mg iv at day1-3, 7.5mg po at day4-5).During the treatment, any grade of nausea and vomiting should be recorded in order to evaluate the complete response rate of CINV, other side-effects should be recorded.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. completion date: May 2016
• Est. primary completion date: May 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Patient who was confirmed lung cancer by pathologic histology or cytology.

2. Males or females aged =18 years, <80 years.

3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Life expectancy =12 weeks.

4. Males and females should be contraceptive during the period of the trial until 8 weeks after the last administration of the drug.

5. Patients with asymptomatic, treated brain metastases are eligible for trial participation.

6. Adequate bone marrow, renal, and liver function are required.

7. Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.

8. Institutional review board-approved informed consent will be obtained for every patient before initiation of any trial-specific procedure or treatment.

Exclusion Criteria:

1. History of sensitivity/idiosyncrasy to aprepitant or excipients

2. Condition that might interfere with drug absorption, distribution metabolism or excretion.

3. Concomitant use of agents that are known to interfere with aprepitant pharmacokinetics

4. Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).

5. Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or have active peptic ulcer disease.

6. Female subjects should not be pregnant or breast-feeding.

7. Inadequate hematological function.

8. Abnormal liver and renal function.

9. Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Chemotherapy-Induced Nausea and Vomiting
• Lung Cancer
• Lung Neoplasms
• Nausea
• Vomiting

Intervention

Drug:
• Aprepitant
Aprepitant:The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3
• Palonosetron

• Dexamethasone

Locations

Country	Name	City	State
China	The first affiliated hospital, Zhejiang University	Hangzhou	Zhejiang

Sponsors (2)

Lead Sponsor	Collaborator
Zhejiang University	Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

China, 

References & Publications (1)

Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy. Intern Med J. 2013 Jan;43(1):73-6. doi: 10.1111 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete Response	The primary endpoint is the overall rate of patients achieving a complete response (defined as no emetic episode and no use of rescue medication) during the overall phase	5 days after the end of chemotherapy	No
Secondary	Complete Control (No emetic episode, no need for rescue medication, with a maximum grade of mild nausea)	No emetic episode, no need for rescue medication, with a maximum grade of mild nausea	5 days after the end of chemotherapy	No
Secondary	Emesis-free	Percentage of patients without emetic episodes	5 days after the end of chemotherapy	No
Secondary	Presence of nausea	Presence of nausea graded according to Likert scale (none, mild, moderate and severe)	5 days after the end of chemotherapy	No
Secondary	Safety and tolerability (adverse events related to study drug administration)	Number of patients experienced at least one adverse events related to study drug administration.	5 days after the end of chemotherapy	No